Novo Nordisk A/S (NYSE:NVO) Shares Unloaded Rep. Lisa C. McClain

Key Points

• Representative Lisa C. McClain sold shares of Novo Nordisk A/S valued between $1,001 and $15,000 on August 4th, according to a filing dated September 12th.
• Novo Nordisk A/S reported a quarterly EPS of $0.97, beating estimates, and has a current market cap of $255.35 billion.
• The company declared a semi-annual dividend of $0.4119, representing a yield of 240.0%, with a payout ratio of 22.53%.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on September 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on August 4th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $50,001 - $100,000 in shares of Taiwan Semiconductor Manufacturing NYSE: TSM on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of ACI Worldwide NASDAQ: ACIW on 8/19/2025.
• Purchased $1,001 - $15,000 in shares of HCA Healthcare NYSE: HCA on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Amedisys NASDAQ: AMED on 8/18/2025.
• Purchased $1,001 - $15,000 in shares of Kite Realty Group Trust NYSE: KRG on 8/13/2025.
• Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of JD.com NASDAQ: JD on 8/13/2025.
• Sold $1,001 - $15,000 in shares of Trade Desk NASDAQ: TTD on 8/13/2025.
• Sold $1,001 - $15,000 in shares of US Foods NYSE: USFD on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Agree Realty NYSE: ADC on 8/13/2025.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $57.19 on Wednesday. The company's 50-day moving average price is $57.44 and its 200-day moving average price is $65.86. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $135.20. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company has a market cap of $255.35 billion, a PE ratio of 15.71, a price-to-earnings-growth ratio of 2.11 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's payout ratio is presently 22.53%.

Institutional Trading of Novo Nordisk A/S

Several institutional investors and hedge funds have recently bought and sold shares of NVO. Copeland Capital Management LLC raised its position in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares during the last quarter. North Capital Inc. purchased a new stake in Novo Nordisk A/S in the 1st quarter valued at $27,000. Park Square Financial Group LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at $29,000. Stone House Investment Management LLC acquired a new position in Novo Nordisk A/S in the 1st quarter valued at $30,000. Finally, NewSquare Capital LLC increased its stake in Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company's stock valued at $31,000 after buying an additional 282 shares during the period. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. BNP Paribas Exane raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price target for the company in a research report on Wednesday, August 13th. UBS Group cut shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. BNP Paribas upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. Finally, Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $81.00.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.